A complete LOI framework and negotiation guide built for mental health clinic acquisitions — covering payer contracts, credentialing risk, MSO structure, and owner-clinician transition terms before you commit to due diligence.
Acquiring a behavioral health practice involves a set of deal complexities that generic LOI templates completely miss. Before you spend $20,000–$50,000 on legal and accounting due diligence, your letter of intent must address the structural and regulatory realities of the mental health industry: corporate practice of medicine laws that may require an MSO structure, insurance panel credentialing that can take 6–18 months to transfer or reestablish, key-person risk tied to an owner-clinician providing the majority of billable services, and HIPAA obligations that govern how patient records and billing data are accessed during the process. This guide walks through every section of a behavioral health LOI with specific example language, explains what is and is not market-standard in the $1M–$5M revenue segment, and identifies the negotiation points most likely to kill a deal or create post-closing regret. Whether you are a private equity-backed roll-up platform, a regional group practice operator, or a clinician acquiring your first multi-provider practice with SBA financing, this template gives you a deal-specific starting point that reflects how behavioral health acquisitions actually get structured.
Find Behavioral Health Practice Businesses to AcquireParties and Practice Identification
Identifies the buyer entity, the seller entity, and the specific practice being acquired. In behavioral health, this section must distinguish between the professional clinical entity (e.g., a professional corporation or PLLC) and any existing management services organization. If the seller operates under both structures, both must be named. If the buyer intends to form a new MSO to comply with corporate practice of medicine laws in the target state, that intent should be noted here.
Example Language
This Letter of Intent is entered into between [Buyer Entity Name], a [State] [LLC/Corporation] ('Buyer'), and [Seller Name], a licensed [psychologist/LCSW/psychiatrist] and owner of [Practice Legal Name], a [Professional Corporation/PLLC] dba [Practice Trade Name] ('Seller' or 'Practice'), providing outpatient behavioral health services located at [Address]. Buyer intends to acquire [the assets of / the equity interests in] the Practice, and if required under [State] corporate practice of medicine law, to establish a Management Services Organization ('MSO') to provide non-clinical administrative services to the licensed clinical entity post-closing.
💡 Confirm the legal structure of the clinical entity before drafting. In corporate practice of medicine states such as California, Texas, and New York, a buyer that is not a licensed clinician cannot directly own the professional entity and must use an MSO structure. Identifying this early prevents a complete restructure of the deal post-LOI. Also confirm whether the trade name, NPI numbers, and payer contracts are held by the professional entity or a separate DBA.
Transaction Structure
Defines whether the deal is structured as an asset purchase or stock purchase, and whether an MSO structure will be layered in. Asset purchases are most common in behavioral health to avoid inheriting unknown liabilities including billing compliance issues, licensing board complaints, or undisclosed payer audits. Stock purchases are used by platform acquirers seeking to preserve existing payer contracts and credentialing relationships, which can be difficult or impossible to transfer in an asset deal.
Example Language
The proposed transaction will be structured as an asset purchase, with Buyer acquiring substantially all of the operating assets of the Practice including but not limited to: all payer contracts and insurance panel enrollments (to the extent assignable or re-credentialable), the EHR system and patient records (subject to HIPAA-compliant transfer protocols), clinical staff employment or contractor agreements, the practice trade name and website, referral relationships, and all tangible office assets. Simultaneously, Buyer will establish a Management Services Organization ('MSO') to employ administrative staff and provide non-clinical management services to [New Clinical Entity Name], a licensed professional entity to be formed and owned by [Licensed Clinician Name] pursuant to a Management Services Agreement with terms acceptable to both parties. Alternatively, if Buyer determines that a stock acquisition better preserves existing payer credentialing, the parties agree to negotiate in good faith to restructure as an equity purchase of the professional entity.
💡 The asset vs. stock decision in behavioral health is heavily driven by payer credentialing strategy. In a stock purchase, existing payer contracts typically survive because the legal entity does not change. In an asset purchase, payer contracts must be renegotiated or re-credentialed, which can take 6–18 months and create a revenue gap. Buyers using SBA 7(a) financing will almost always require an asset purchase. If the seller has any unresolved billing audits, payer overpayment demands, or licensing board matters, an asset purchase provides critical liability protection.
Purchase Price and Valuation Basis
States the proposed total consideration, the valuation methodology, and the financial metrics the offer is based on. Behavioral health practices in the $1M–$5M revenue range typically trade at 3.5x–6x adjusted EBITDA, with the multiple driven by payer mix quality, clinician diversification, and service line breadth. The LOI should specify trailing twelve month or seller's discretionary earnings figures as represented by the seller, and note that the final price is subject to financial due diligence verification.
Example Language
Based on Seller's represented trailing twelve-month (TTM) net revenue of approximately $[X] and adjusted EBITDA of approximately $[X], reflecting add-backs for owner compensation above market-rate replacement salary, personal vehicle expenses, and one-time facility costs, Buyer proposes a total enterprise purchase price of $[X], representing a multiple of approximately [X]x adjusted EBITDA. This valuation assumes: (i) no single licensed clinician, including the owner, accounts for more than [30%] of total billable collections; (ii) the Practice maintains contracts with at least [5] commercial and/or government payers; and (iii) no material billing compliance issues, payer audits, or licensing board actions are identified during due diligence. The purchase price is subject to adjustment based on verified financial performance and due diligence findings, including payer mix analysis and credentialing status review.
💡 Sellers frequently present revenue figures that include owner-clinician collections that cannot be replicated post-sale without a licensed replacement. Push sellers to provide a 'replacement-adjusted' EBITDA that accounts for the cost of a market-rate replacement clinician before arriving at the multiple. A practice with $500,000 in EBITDA that drops to $200,000 after replacing the owner-clinician at a $200,000 salary should be valued on the adjusted figure. Also confirm whether revenue is reported on a cash or accrual basis and whether insurance remittance reports reconcile to tax returns.
Payment Structure and Sources of Funds
Details how the purchase price will be funded, including equity, SBA or conventional debt, seller note, and any earnout component. Behavioral health deals frequently use SBA 7(a) loans for acquisitions under $5M in enterprise value, with seller notes of 10–20% subordinated to the SBA lender. Earnouts tied to patient census retention or clinician headcount are common where key-person risk is elevated.
Example Language
The proposed payment structure is as follows: (i) $[X] in cash at closing, funded through a combination of Buyer's equity contribution of $[X] and an SBA 7(a) loan of $[X] from [Lender Name or TBD]; (ii) a seller-carried promissory note of $[X] (representing approximately [15%] of the total purchase price), subordinated to the SBA lender, bearing interest at [6–7]% per annum, amortized over [5] years with principal payments commencing [12] months post-closing; and (iii) a contingent earnout of up to $[X] payable over [24] months post-closing, calculated based on [patient census retention above 80% of the trailing twelve-month average] and [licensed clinician headcount remaining at or above 8 FTE]. The earnout shall be measured and paid [quarterly/annually] and is subject to Buyer's right of offset for any indemnification claims.
💡 Sellers should understand that SBA lenders will require them to sign a personal guarantee standby agreement on the seller note, meaning they cannot receive note payments if the SBA loan is in default. Earnout terms must be defined with mathematical precision — vague language like 'patient retention' creates post-closing disputes. Specify whether the earnout is measured by number of active patients, total session volume, or gross collections, and who is responsible for clinician retention efforts during the earnout period. Buyers should resist tying earnouts solely to metrics outside their control, such as insurance reimbursement rate changes.
Seller's Employment and Transition Agreement
Defines the owner-clinician's post-closing role, duration, compensation, and clinical obligations. This is one of the most critical sections in any behavioral health LOI because patient relationships and referral sources are often entirely dependent on the selling clinician. A poorly structured transition creates immediate patient attrition and referral source confusion.
Example Language
As a condition of closing, Seller agrees to enter into an employment or clinical services agreement with [New Clinical Entity / MSO] for a period of no less than [24] months post-closing ('Transition Period'), during which Seller shall: (i) continue providing clinical services at no less than [60%] of current weekly session volume for the first [12] months, transitioning to [30%] in months 13–24; (ii) introduce Buyer's designated successor clinicians to existing referral sources including primary care physicians, hospital discharge coordinators, school counselors, and EAP program managers; (iii) participate in staff retention efforts and culture integration activities as reasonably requested by Buyer; and (iv) refrain from soliciting patients, clinicians, or referral sources for any competing behavioral health practice within [25] miles of the Practice's primary location for a period of [3] years post-closing. Seller's compensation during the Transition Period shall be $[X] per annum plus [clinical productivity incentives tied to session volume above baseline].
💡 Non-compete and non-solicitation enforceability varies significantly by state, and several states including California severely restrict or prohibit non-compete enforcement even in business sale contexts. Consult state-specific counsel before finalizing any restrictive covenant language. Sellers should negotiate for a transition period that is long enough to be compensated but short enough to allow eventual return to independent practice if desired. Buyers should prioritize non-solicitation of staff and referral sources over broad geographic non-compete clauses, as staff poaching post-closing is the more common and damaging risk.
Conditions to Closing
Lists the material conditions that must be satisfied before the transaction can close. In behavioral health, standard closing conditions must be expanded to address clinician credentialing, licensing transfers, payer contract assignability, HIPAA-compliant patient record transfer protocols, and any required regulatory filings in the target state.
Example Language
Closing of the proposed transaction is conditioned upon: (i) satisfactory completion of Buyer's due diligence, including review of all payer contracts, clinician credentialing files, HIPAA compliance documentation, EHR data, billing records for the trailing 36 months, and financial statements for the trailing 3 fiscal years; (ii) confirmation that no licensed clinician is subject to an active licensing board complaint, DEA investigation, or payer exclusion list designation; (iii) execution of employment or independent contractor agreements with no fewer than [6] of the Practice's currently active licensed therapists and/or psychiatrists; (iv) receipt of SBA lender approval and commitment letter; (v) execution of a Management Services Agreement between the Buyer's MSO and the licensed clinical entity on terms acceptable to both parties; (vi) confirmation of payer contract transferability or credentialing plan acceptable to Buyer for all payers representing more than [10%] of trailing revenue; and (vii) no material adverse change in patient census, clinician headcount, or payer reimbursement rates between LOI execution and closing.
💡 The credentialing condition is the most deal-sensitive item in behavioral health. Buyers must confirm whether payer contracts can be assigned in an asset purchase or whether re-credentialing is required, as some payers will not transfer contracts under any circumstances and will require the new entity to apply fresh, creating a 6–18 month revenue gap. Request copies of all payer contracts during due diligence and have a healthcare attorney review assignability clauses before waiving this condition. The clinician retention condition should be written as a closing condition, not just a post-closing earnout trigger.
Exclusivity and No-Shop
Grants the buyer an exclusive period to complete due diligence and negotiate a definitive purchase agreement, during which the seller agrees not to solicit or entertain offers from other buyers. Standard exclusivity periods in behavioral health acquisitions range from 60–90 days given the complexity of credentialing and regulatory review.
Example Language
In consideration of Buyer's commitment of time and resources to due diligence, Seller agrees that from the date of execution of this Letter of Intent through the earlier of (i) [90] calendar days or (ii) termination of this LOI by either party, Seller shall not directly or indirectly solicit, initiate, encourage, or participate in discussions or negotiations with any third party regarding the sale, merger, recapitalization, or other transfer of all or a material portion of the Practice. Seller shall promptly notify Buyer if Seller receives any unsolicited inquiry or offer from a third party during the exclusivity period. Buyer agrees to conduct due diligence and negotiate in good faith toward a definitive purchase agreement during the exclusivity period.
💡 Ninety days is appropriate for behavioral health given the complexity of credentialing review, HIPAA-compliant data room setup, and SBA lender underwriting timelines. Sellers should resist exclusivity periods longer than 90 days without a milestone-based extension trigger. Sellers should also confirm that the exclusivity clause does not prevent them from discussing transition plans with key clinicians, which is necessary for staff retention planning. Buyers who are slow to deliver a diligence checklist or LOI counter should not expect sellers to indefinitely extend exclusivity.
Confidentiality and HIPAA Obligations
Addresses the handling of sensitive practice information during due diligence, with specific provisions for protected health information (PHI) governed by HIPAA. Unlike most business acquisitions, behavioral health due diligence involves patient records, therapy notes, and billing data that carry federal privacy obligations independent of any NDA.
Example Language
The parties acknowledge that in connection with Buyer's due diligence, Seller may provide access to information that constitutes Protected Health Information ('PHI') as defined under HIPAA and its implementing regulations. The parties agree to execute a Business Associate Agreement ('BAA') prior to Buyer's access to any PHI, and Buyer agrees to: (i) access only the minimum necessary PHI required for due diligence purposes; (ii) implement appropriate administrative, physical, and technical safeguards to protect PHI from unauthorized access or disclosure; (iii) not use or disclose PHI for any purpose other than evaluating the proposed transaction; and (iv) destroy or return all PHI upon termination of this LOI if the transaction does not close. All other non-public business information shared during due diligence shall be governed by the Mutual Non-Disclosure Agreement executed by the parties on [date], which is incorporated herein by reference.
💡 Many buyers underestimate HIPAA's applicability in behavioral health M&A due diligence. Access to billing records, EHR exports, and even session volume data tied to identifiable patients may constitute PHI access requiring a BAA. Failure to execute a BAA before accessing such information is a HIPAA violation that can expose both parties to regulatory liability. Ensure your M&A attorney has healthcare privacy experience, not just general M&A expertise. The BAA requirement should be treated as a pre-condition to opening the data room, not an afterthought.
Binding and Non-Binding Provisions
Clearly identifies which sections of the LOI are legally binding and which represent non-binding expressions of intent. This section protects both parties — the buyer from being locked into a deal price before due diligence is complete, and the seller from a buyer who uses the LOI to take the practice off the market and then re-trades the price.
Example Language
The parties acknowledge and agree that this Letter of Intent is intended to be non-binding with respect to the proposed transaction structure, purchase price, and payment terms, which are subject to completion of due diligence and execution of a definitive Purchase Agreement. Notwithstanding the foregoing, the following provisions shall be legally binding upon execution: (i) the Exclusivity and No-Shop provisions in Section [7]; (ii) the Confidentiality and HIPAA obligations in Section [8]; (iii) each party's obligation to bear its own costs and expenses in connection with the proposed transaction unless otherwise agreed in a definitive agreement; and (iv) the governing law and dispute resolution provisions of this LOI. This LOI does not constitute a binding commitment to consummate the proposed transaction and either party may terminate discussions at any time prior to execution of a definitive Purchase Agreement.
💡 Sellers frequently sign LOIs without fully understanding that the purchase price is not locked in until a definitive agreement is signed. Buyers routinely re-trade price after due diligence reveals issues with billing practices, payer concentration, or clinician turnover. Sellers should insist on a good faith re-trade provision stating that any price reduction must be supported by documented due diligence findings, not simply buyer's changed appetite. Both parties should have their own legal counsel review the binding vs. non-binding distinction before signing.
Payer Contract Transferability and Credentialing Gap Coverage
Behavioral health payer contracts — especially with commercial insurers like Aetna, Cigna, BlueCross, and United — are frequently non-assignable and require the buying entity to re-credential as a new provider. This process takes 6–18 months and creates a revenue gap during which the practice cannot bill under insurance panels. Buyers should negotiate a purchase price adjustment mechanism or a revenue guarantee from the seller if credentialing is interrupted post-closing. Sellers should resist broad credentialing risk allocation and push for a defined escrow or holdback release tied to credentialing milestones rather than a blanket price reduction.
Owner-Clinician Earnout Metrics and Control Rights
When a portion of the purchase price is deferred as an earnout tied to patient census or clinician retention, the parties must negotiate who controls the variables that determine the payout. If the buyer changes the practice's fee schedule, stops accepting a major payer, or terminates clinicians during the earnout period, the seller's earnout can be destroyed through no fault of their own. Sellers should negotiate for specific buyer conduct restrictions during the earnout period, including minimum staffing obligations and prohibitions on unilateral payer contract terminations. Buyers should resist any earnout structure where the seller controls day-to-day clinical scheduling or referral source management post-closing, as this undermines the buyer's operational authority.
MSO Management Fee Structure and Clinical Entity Independence
In corporate practice of medicine states, the MSO structure requires the clinical professional entity to be legally independent and owned by a licensed clinician, with the MSO providing only non-clinical services for a management fee. The management fee percentage — typically 85–95% of the clinical entity's net revenue — must be negotiated carefully to comply with state law while still delivering meaningful economic return to the buyer. If the fee is set too high, regulators may challenge the arrangement as unlawful fee-splitting. Buyers should obtain a healthcare attorney opinion on the appropriate fee range in the target state, and both parties should confirm the licensed nominal owner of the clinical entity has genuine control over clinical decisions.
Clinician Non-Solicitation and Key Employee Retention Commitments
The departure of 2–3 licensed therapists or a psychiatrist following an acquisition announcement can immediately collapse the revenue thesis. Both parties should negotiate a clinician retention plan as part of the LOI, including stay bonuses funded by the buyer or seller, employment agreement requirements as a closing condition, and non-solicitation obligations preventing the selling owner from poaching staff post-closing. Buyers should specify the minimum number of licensed clinicians required at closing and tie a portion of the seller's consideration — typically 10–15% — to a post-closing clinician retention escrow released over 12–18 months. Sellers should resist broad non-solicitation clauses that prevent them from simply hiring clinicians who independently choose to leave the practice after the sale.
HIPAA Compliance Representations and Billing Audit Liability
Behavioral health practices frequently have undetected billing compliance exposure including upcoded CPT codes, incorrect modifier usage, unbundled services, and failure to document medical necessity for higher-intensity services. In an asset purchase, the buyer does not inherit pre-closing liabilities, but payer overpayment demands can follow the payer contracts themselves if not addressed. The LOI should specify that the seller will represent and warrant clean billing practices and will be responsible for any overpayment demands, audit findings, or compliance penalties arising from pre-closing billing periods, with a holdback or indemnification escrow sized at 10–15% of the purchase price held for 18–24 months. Buyers should conduct a billing compliance review as part of due diligence before waiving this condition.
Find Behavioral Health Practice Businesses to Acquire
Enough information to write a strong LOI on day one — free to join.
Whether you need an MSO structure depends on the state where the practice operates. Approximately 30 states have corporate practice of medicine laws that prohibit non-clinician entities from directly owning a licensed professional practice. In these states, buyers who are not licensed clinicians must structure the acquisition as an asset purchase into a new clinical entity owned by a licensed clinician, with a Management Services Organization providing administrative and management services under a long-term MSO agreement. The LOI should explicitly address this structure if the target state requires it, because retrofitting an MSO arrangement after signing a stock purchase LOI creates significant legal and tax complications. Your healthcare attorney should confirm the applicable state doctrine before the LOI is executed.
Payer contracts are often the most valuable asset in a behavioral health acquisition, and they are also the most structurally complex to transfer. Most commercial payer contracts — and nearly all Medicare and Medicaid provider agreements — are non-assignable and require the acquiring entity to apply for new provider enrollment and credentialing. This process typically takes 6–18 months, during which the practice cannot bill insurance under the new entity's NPI. Buyers using an asset purchase structure must have a credentialing strategy in place before closing, which often involves the selling clinician continuing to bill under their existing credentials during a transition period. The LOI should address how this credentialing gap will be managed and who bears the financial risk if credentialing is delayed. Buyers who want to preserve existing payer contracts should consider a stock purchase, which maintains the contracting legal entity, though this carries greater liability exposure.
Yes, behavioral health practices are SBA-eligible businesses, and SBA 7(a) loans are one of the most common financing tools used by individual buyers and small operators acquiring practices in the $1M–$5M revenue range. SBA loans can finance up to 90% of the purchase price, with typical down payments of 10% from the buyer. The LOI should reflect SBA financing as the funding source because it imposes specific structural requirements: the deal must typically be structured as an asset purchase, the seller note must be on full standby for the first 24 months of the SBA loan, and the seller cannot retain more than 20% equity in the post-closing entity. SBA lenders will also underwrite the practice's cash flow to confirm debt service coverage, so the LOI purchase price should be calibrated to what the practice's adjusted EBITDA can actually support under SBA debt service requirements, typically a 1.25x coverage ratio.
A 60–90 day exclusivity period is standard for behavioral health acquisitions in the lower middle market. The additional time compared to simpler business acquisitions is justified by the complexity of credentialing due diligence, HIPAA-compliant data room setup, MSO structure documentation, SBA lender underwriting, and state licensing review. The exclusivity provision should be legally binding and should explicitly prohibit the seller from soliciting, entertaining, or accepting offers from other buyers during the period, with a notice obligation if unsolicited interest is received. Buyers who miss due diligence milestones or fail to deliver a term sheet within the exclusivity period should expect sellers to demand expiration rather than extension. Both parties should agree on a mutual termination right with 5 business days notice if the process stalls, so neither party is left in an indefinite holding pattern.
Behavioral health practices in the lower middle market typically trade at 3.5x–6x adjusted EBITDA, with the multiple driven by several practice-specific factors. Practices at the lower end of the range typically have heavy owner-clinician dependence where the owner provides more than 40% of billable services, single-payer concentration particularly with Medicaid, limited staff depth with fewer than 5 licensed clinicians, and no documented referral source relationships. Practices commanding 5x–6x multiples typically have diversified revenue across 8 or more licensed clinicians, strong commercial payer mix with contracted rates, telehealth infrastructure, recurring IOP or group therapy revenue, and a clean HIPAA compliance record. Platform acquirers and private equity-backed roll-ups may pay at or above the top of this range for practices in high-density markets with established brand recognition, but individual buyers using SBA financing are generally constrained to multiples where the debt service is supportable by the verified adjusted EBITDA.
More Behavioral Health Practice Guides
More LOI Templates
Get enough diligence data to write a confident LOI from day one.
Create your free accountNo credit card required
For Buyers
For Sellers